Increasing evidence has demonstrated that GLP-1 analogues can cross the blood-brain barrier, protect dopaminergic neurons in the substantia nigra, and rescue motor activity and cognitive functions in PD animal models (59–61). Here, GLP1R is linked to Parkinson disease.